Human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) are emerging as a powerful in vitro model for cardiac safety assessment which may allow for better identification of compounds with poor arrhythmogenic liability profiles early in the drug discovery process. Here, we describe our examination of the Kinetic Image Cytometer (KIC) system's ability to predict adverse compound effects using hiPS-CMs and a library of 53 compounds, the majority of which are known to be cardioactive compounds, and several negative controls. The KIC provides a high throughput method for analyzing intracellular calcium transients. In the cardiomyocyte, intracellular calcium transients integrate the electrochemical signals of the action potential (AP) with the molecular signaling pathways regulating contraction. Drug-induced alterations in the shape and duration of AP result in changes to the shape and duration of the intracellular calcium transient. By examining calcium transient dynamics in hiPS-CMs, KIC can be used as a phenotypic screen to assess compound effects across multiple ion channel types (MITs), detecting MITs, calcium handling and signaling effects. The results of this blinded study indicate that using hiPS-CMs, KIC is able to accurately detect drug-induced changes in Ca 2þ transient dynamics (ie, duration and beat rate) and therefore, may be useful in predicting drug-induced arrhythmogenic liabilities in early de-risking within the drug discovery phase.
but relevant, preclinical screening methods to de-risk these new compounds.
Although the preclinical safety assessment approaches of some companies currently provides sufficient indications of risk, the process is often complex and incorporates many in vitro and in vivo assays involving preparations coming from multiple animal species, which is not always fully translatable to humans. Furthermore, with an increasing focus on the 3R's (Replace, Reduce, Refine) in relation to animal studies, the incentive for this research was to assess whether we could simplify the current in vitro approach, and do so in a humanized platform in order to prioritize compounds before animal studies were undertaken.
Predicting whether a potential new therapeutic compound can induce arrhythmias remains a major component in the drug development process. It has recently been recognized by both the pharmaceutical industry, and the global regulatory bodies which monitor the safety of pharmaceutical drugs, that the current toolbox of in vitro arrhythmogenic liability assays and model systems for early de-risking has some potential shortcomings which may be having profound negative effects on drug development pipelines (Sager et al., 2014) . This is primarily driven by the concern of regulators that companies may be eliminating potentially useful therapeutic compounds from the pipeline based on hERG (human ether-à -go-go related gene) results alone, without trying to understand whether they are actually proarrhythmic. Current approaches to early stage, high throughput safety testing generally oversimplify the complexities of cardiac physiology and excitation by using models and assay systems which only allow compound effects to be assessed on 1 ion channel at a time, typically the hERG channel. However, compounds administered in vivo often affect the activities of several ion channels simultaneously, and predicting the overall effect on the action potential (AP) for compounds with mixed channel effects using single ion channel assessments can be difficult, if not impossible. For example, several drugs are known to block hERG, but have been used safely in humans for many years due to concomitant effects on other channels or on signaling pathways which balance the effects of hERG blockade, eg, ranolazine (Schramm et al., 2004) and verapamil (Yang et al., 2001) . Current single ion channel assays cannot predict these interactions, and potentially beneficial and safe drugs which happen to block the hERG channel are therefore being removed from the development pipeline. Additionally, compounds which may have potentially deleterious effects on cardiac electrophysiology that are not caused by hERG channel block may be advanced, only to fail at later stages of development.
Human stem cell (hSC)-derived cardiomyocytes have emerged as a potentially useful model for cardiac safety assessment. These cells express the full complement of cardiac ion channels, generate APs and calcium transients and demonstrate contractile motion (Ma et al., 2011) . As a result these cells can be used to assess compound effects across the full array of ion channels. Additionally, they are produced in large quantities, making them compatible for high throughput assays. To utilize the full potential of these cells, assay systems that can analyze an integrated signal which can be used to examine compound effects across the full spectrum of cardiac ion channels, and which take into account multichannel and signaling effects, are needed.
Changes in the activities of 1 or more of the component ion channels due to compound exposure can result in changes in the shape and duration of the cardiac AP, some of which have been linked to the induction of arrhythmias. The intracellular calcium transient is the second messenger which links the electrochemical signals of the AP to contractile motion of the cell (Bers, 2002) . Consequently, any changes in the shape and duration of the AP are expected to be reflected in a change in the shape and duration of the calcium transient. Therefore, the intracellular calcium transient could potentially be used as a surrogate marker for examining compound effects on cardiac repolarization, while also identifying any potential effects on calcium handling and other signaling pathways which effect contraction of the cell.
Early proof of principle for this approach was shown by Qian and Guo (2010) using a panel of both cardiotoxic and safe drugs in an adult guinea-pig cardiomyocyte model. Their study used manual microscopy methods to record calcium transients from 1 cardiomyocyte at a time, which is not compatible with the type of high throughput processing required for an early stage de-risking tool. In our previous report, we described methods which greatly increase the throughput and accuracy of calcium transient assays (cell-by-cell measurements on hundreds of cells per well and hundreds to thousands of wells per day), and which have the advantage of utilizing hSC-derived cardiomyocytes (Cerignoli et al., 2012) . The automated Kinetic Image Cytometer (KIC) which is used in this assay was designed to record and analyze intracellular calcium transients in individual cells from hundreds of cells per well in a high throughput manner. The ability to perform cell-by-cell measurements, as opposed to full field analysis, increases the sensitivity of the assay by eliminating the noise introduced by propagation of the signal across the field of view, and from any asynchrony of the cells. Furthermore, this cell-by-cell approach has the ability to isolate calcium transient signals from specific intracellular regions. This means that the calcium transient signals within the nuclear compartment, which are at least partially dependent on diffusion, can be removed from the analysis, and the intracellular calcium transient signal directly associated with the release and reuptake of calcium into the sarcoplasmic reticulum can be analyzed specifically. Additionally, the use of standard multi-well plates and the compatibility with conventional compound-handling robotics supports the necessary throughput for an assay of this type to be deployed at the early de-risking stages within drug discovery. This novel technique of high throughput screening (HTS) using KIC technology has already been shown to be useful in identifying new targets for drug discovery (Wahlquist et al., 2014) .
Although the development of such novel methods is technically satisfying, and scientifically interesting, a comprehensive characterization of this approach, using many reference drugs, at different concentrations, as described in Pugsley et al. (2011) is needed for comparison with currently applied screening models. Here, we describe the results of a complete, blinded characterization of a screen of 53 compounds with many different mechanisms of action. Many are standard drugs with known adverse cardiac effects, others are reference compounds known to be cardioactive, and several inactive compounds have been included as negative controls (all in random order). For understanding the reproducibility of the screen, several of the compounds were tested in duplicate or even in triplicate, resulting in a total of 60 tests in this characterization study.
The results reported in this study demonstrate the potential usefulness of this high content assay for detecting the varied effects of such compounds. Few compounds are completely specific in their mechanisms, and several of the compounds tested are known to affect multiple ion channels simultaneously. These "mixed channel" compounds had clear effects on the calcium transients recorded in this screen and were readily identified. The results demonstrate that the HTS methods described in this report, and in the first part of this study (Cerignoli et al., 2012) , provide an effective assay for screening novel compounds for cardioactivity in a human cardiomyocyte model which may have advantages over current screening assays. Not only does it yield much more information than the basic ICH "S7B (International Committee on Harmonization Guideline S7B)recommended" hERG test, but it provides an integrated response from an intact, physiologically relevant, human-based model system.
MATERIALS AND METHODS
Methodological details of the KIC have been published in the first part of this study (Cerignoli et al., 2012) , but are summarized below for completeness. The study was conducted by Vala Sciences in a blinded manner and all compounds were provided blinded by Janssen.
Culturing of iCell cardiomyocytes from Cellular Dynamics
International. On delivery the cryopreserved cells were transferred to liquid nitrogen storage where they remained, in the vapor phase, until being plated. Differentiation and purification methodology for iCell Cardiomyocytes (Cellular Dynamics International, Madison, Wisconsin) are published (Ma et al., 2011) . Cells were thawed and plated, per the manufacturer's suggested protocol, onto Matrigel (BD Biosciences, San Jose, California) (250 mg/ml)-coated 96 well film-bottom plates (Greiner, Monroe, North Carolina) at a density of 18 000 cells per well. The cells were maintained for the first 2 days in Cellular Dynamics International (CDI's) plating medium at 37 C and 7% CO 2 . After 2 days in culture the plating media was replaced with CDI maintenance media; the cells continued to be maintained at 37 C and 7% CO 2 and maintenance media was replaced every other day. Cells were cultured for 10 days post-thaw prior to the experiments being performed. The cardiomyocytes formed a monolayer and displayed spontaneous beating within 48 h of being plated and maintained this phenotype throughout the duration of the experiment. All cells used in these experiments were from the same production lot.
Loading of cardiomyocytes with indicator dyes and exposure to test compounds. Prior to treatment with the test compounds the cardiomyocytes were loaded with Hoechst 33342 (Invitrogen Carlsbad, CA, USA) (to visualize nuclei) and Fluo-4 No-Wash (Fluo-4 NW, Invitrogen Carlsbad, California) (to visualize calcium transient) for 1 h at 37 C. Fluo-4 NW is a relatively bright and photostable fluorescent reporter of intracellular calcium exhibiting relatively little calcium buffering (Paredes et al., 2008) , Kd 345 nM (Gee et al., 2000) , and was loaded using one-fourth the manufacturer's suggested concentration. 100 ng/ml Hoechst 33342, and 2.5 mM probenecid were also included in the supplied Fluo-4NW assay buffer. Following dye loading, the cells were washed twice with a modified Tyrode's solution (140 mM NaCl, 6 mM KCl, 1 mM MgCl 2 , 25 mM HEPES, 2 mM CaCl 2 , 10 mM D-(þ)-Glucose, pH 7.4). The test compounds, diluted in Tyrode's buffer (which contained no protein, so that the potency of compounds in the assay would not be affected by protein binding) and warmed to 37 C, were then added to the appropriate wells. The cardiomyocytes were equilibrated in the imaging chamber with test compounds and Tyrode's buffer at 37 C for 10 min prior to being imaged, temperature maintained at 37 C. The effects of each test compound were analyzed at 4 different concentrations, in triplicate for each test concentration. The final dimethyl sulphoxide (DMSO) concentration for all test compounds and vehicle controls was 0.1%. Vehicle controls receiving 0.1% DMSO alone were distributed throughout each plate. 48 wells on each plate were used, partly to avoid plate "edge effects," and partly to reduce the run time per plate to minimize dye leakage.
Kinetic imaging of calcium transients. An IC200-KIC high content instrument (Vala Sciences Inc., San Diego, California) was used to make digital recordings of the intracellular calcium transients. For these experiments the KIC instrument was fitted with a 20Â objective and captured 1 image of the nuclei (Hoechst), then recorded 10 s of calcium transient activity at 30 fps (frames per second) from spontaneously beating cells. Run time is approximately 15 min per plate of 48 wells.
Transient analysis with CyteSeer. Calcium transient analysis was performed using Vala Sciences' CyteSeer automated image analysis software (Cerignoli et al., 2012) . CyteSeer identifies, segments, and indexes each cell in each field of view to allow for cell-by-cell reporting of Ca 2þ transient measurements. Each cell is then further segmented and calcium transient analysis is performed within a specified subcellular region. For this study calcium transients within the cytoplasmic area of the cell, which relate primarily to the release and reloading of calcium into the sarcoplasmic reticulum, were analyzed. Calcium transients were automatically identified and measured algorithmically using the CyteSeer software. Gating parameters were applied to wells to remove nonresponding cells from the analysis. Measured parameters of transients from approximately 200-400 cells were thus collected and averaged per well, then averaged across all wells per dose. Ten different Ca 2þ transient parameters which describe the shape and duration of the transient were analyzed, as well as the spontaneous beat rate (Figs. 1B and C). To normalize for cell-to-cell variability in dye loading the pixel intensity was normalized to the base line pixel intensity by the equation F-F 0 /F 0 , where F 0 is the baseline fluorescence and F represents the fluorescence intensity at any given time point.
Quality control. Our previous experience with CDI cardiomyocytes was used to develop quality control (QC) procedures for the assay. First, cell quality was monitored daily through visual inspection of the cultures. If any plates showed abnormalities such as, low cell number, abnormal morphology, or contamination, the plates were not used for compound testing.
Once recordings had been made and analyzed the coefficient of variation (CV) for the calcium transient measurements Full Width Half Maximum (FWHM) time, Decay time, and time for the calcium transient to decay from 75% to 25% of maximum (T75-25), a measurement of triangulation, were examined for all sets of controls. If the CV exceeded 20% for any set of controls then the results were excluded for that compound and the plate was rerun (there were no failures of this type during this study).
Finally, BAY K 8644 (1 mM), sotalol (50 mM), and verapamil (300 nM) were included in triplicate on each plate to ensure that there was an effective response to the reference compounds. Minimum acceptable responses were as follows: If the cells did not display an adequate response to the reference compounds the data for the compounds on that plate was excluded and rerun. For this study all 30 plates met the QC requirements and no reruns were necessary.
Testing drugs and protocol. The reference compounds on each plate were acquired by Vala Sciences; sotalol and verapamil were from Sigma Aldrich (St. Louis, Missouri) and BAY K 8644 was from Tocris Bioscience (Bristol, United Kingdom) .
The 53 unique test compounds were provided blind and randomized (with slightly altered molecular weights) by Janssen (see Supplementary Table 1 ). Five of the compounds were provided in duplicate and 1 in triplicate for a total of 60 test compounds. Eight of these compounds were synthesized by Janssen (Beerse, Belgium) (mesoridazine, JNJ-303, ibutilide, propoxyphene, bepridil, carbachol, zatebradine, carbenoxolone). Twenty-one compounds were purchased from Sigma Aldrich (mallotoxin, levcromakalim, flecainide, terfenadine, isoprenaline, ranolazine, digoxin, nicorandil, phenylephrine, pinacidil, primidone, mexiletine, dimenhydrinate, diltiazem, propranolol, aspirin, atropine, cetirizine, BaCl 2 , nitrendipine and procainamide). Dofetilide was purchased from Toslab Limited (Ekaterinburg, Russia). Veratridine and NS1463 were purchased from Tocris Cookson (Bristol, United Kingdom). Forskolin, diphenyl phosphine oxide-1 (DPO-1), E4031, BAY K 8644, ivabradine, tertiapin (peptide), and eliprodil were from Wuxi AppTec (Shanghai, China). Nimodipine, citalopram, and sparfloxacin were from Sequoia Research Products (Pangbourne, United Kingdom). Azithromycin was from Fluka SAF, and 4-aminopyridine and Histamine were from Acros Chimica (Geel, Belgium). Serotonin and glucose were from Alfa Aesar (Ward Hill, Massachusetts) and dl-sotalol was acquired from Bristol-Myers Squibb (New York).
For all test and reference compounds stock solutions were prepared in DMSO at 1000 times the highest concentration to be tested in order to maintain final DMSO concentrations at 0.1%. Compound stocks were aliquoted and stored at À80 C. Drugs were blinded. Each drug was tested at 4 concentrations (n ¼ 3 wells per dose, n ¼ 6 wells per controls).
Statistical analysis and reporting. ANOVA with Dunnett's post hoc analysis was used to compare transient parameters of each treatment group to their respective controls. Abbreviations and symbols: *P < .05, **P < .01, ***P < .001, ns ¼ not significant, nc ¼ not calculated. In addition to statistically significant duration changes, calcium transient prolongation to !175% of control and shortening to 80% of control were reported. Bar charts are presented as mean 6 the standard deviation.
RESULTS

Behavior of the Cells
For cell-based HTS it is essential that the model system being employed be well defined, scalable, easy to use, and show consistent behavior. Preliminary experiments with stem cellderived cardiomyocytes from several different suppliers showed marked variations in beating rate and weaker and FIG. 1. A, Immunofluorescent staining using DAPI (blue) and alpha-actinin (green) reveals that hiPS-CM cultures consist of pure cardiomyocytes with reasonably developed sarcomeric organization. B and C, The KIC assay makes 10 measurements that describe the shape and duration of the transient and the first derivative of the transient. D, Intraplate variability was found to be very low, CV's for the FWHM, T75-25 time, and the CTD75 measurements across all control wells for each of the 30 plates used in this study were found to be 10.0%, 8.8%, 11.85%, and 9.6%, respectively. E, Interplate variability was also found to be very low The mean CV's for the Decay Time, FWHM, T75-25, and CTD75 measurements across all plates were 9.7%, 7.1%, 9.54%, and 7.26%, respectively. F, Similarly, the variability in the beat rate was also found to be very low with a CV of the 8.8% across all 30 plates. varied responses to the reference compounds used for QC. Additionally, those models often contained a mixture of cardiomyocytes and noncardiomyocytes. The cell model selected for use in this study proved easy to work with, had consistent beating rates and electrophysiology ( Supplementary Figure 1) , formed the monolayers required for this kind of assay, and consistently met the predetermined QC standards for this assay (variability was low, and none of the 30 plates used to test the 60 compounds needed to be rerun). Immunofluorescence studies using DAPI and alpha-actinin as relative markers for cardiomyocytes demonstrated that on average the cultures consisted of > 95% cardiomyocytes, and often cultures were found to consist of a pure cardiomyocyte population ( Figure 1A) . Thus, while the cells do not perfectly recreate an adult human ventricular cell (see Limitations, below), the cells used were found to be wholly adequate for use in this high throughput early de-risking screen and we expect that advances in stem cell technology will only improve upon the currently-available models.
Analysis of Calcium Transient Kinetics and Beat Rate
The calcium transients that were recorded with the KIC assay had the characteristic shape of a stem cell derived-cardiomyocyte calcium transient, showing a very rapid upstroke and a biphasic downstroke ( Figure 1B ). As described in our first report, these calcium transients were regular and allowed easy measurement of the beating frequency and various kinetic parameters. Analysis of the control wells revealed that both intraplate and interplate variations were very low. The average intraplate CV for the Decay Time, FWHM, T75-25 time, and the 75% Duration of the Calcium Transient (CTD75) measurements across all control wells for each of the 30 plates used in this study were found to be 10.0%, 8.8%, 11.9%, and 9.6%, respectively. The interplate CVs for the same measurements across all 30 plates were 9.7%, 7.1%, 9.54%, and 7.3%, respectively (Figs. 1D and E). The baseline beating rate for control wells across the 30 plates used in this study was 15.2 6 1.3 beats per minute (mean 6 standard deviation, Figure 1F ). The CV for the beat rate of the control wells across all 30 plates was 8.8%.
Reproducibility of Responses to Reference Compounds
Each plate contained reference compound wells where the calcium transient duration should be prolonged by sotalol (50 mM) and BAY K 8644 (1 mM) and should be reduced by verapamil (300 nM) (Figs. 2A-C). We analyzed the mean response of the cells to each compound, relative to controls, across all 30 plates. The responses were highly reproducible for Sotalol, Verapamil, and BAY K 8644 with CVs for the FWHM measurement of 8.4%, 11.8%, and 10.6%, respectively ( Figure 2D ). The decay time measurement for the same compounds also showed a high degree of reproducibility with CVs of 10.4%, 12.2%, and 12.7%, respectively ( Figure 2E ).
Effects of the Test Compounds on the Calcium Transients of hiPS-CMs as Measured by the KIC Assay
The CyteSeer analysis software package provides multiple measurements that describe the shape and duration of the calcium transients. However, when conducting a large scale screen, trying to incorporate multiple measurements into an early decision-making process can complicate interpretation of the results. After looking at the results from the screen it became obvious that the number of key measurements required to classify the compounds could be significantly reduced. In this study, we found that the most useful parameters for initially identifying compound effects were measurements of the duration of the calcium transient, including the FWHM, Decay time, and T75-25, and CTD75 measurements. These measurements, in combination with changes in the beat rate, were sufficient to identify most compound effects. Therefore, the discussion of the results will focus primarily on changes in transient duration and secondarily beat rate. However, it should be noted that the peak height measurements provide context for understanding possible mechanisms of action. For example, calcium channel blockers such as nitrendipine cause a shortening of the calcium transient duration which is accompanied by a reduction in peak height ( Figure 5A ). The sympathomimetic isoprenaline also causes a shortening of the calcium transient duration; however, isoprenaline causes an increase in the peak height of the calcium transient consistent with its known inotropic effect ( Figs. 6A and B) . The 53 unique compounds were separated into 6 broad classes that included QT (QT interval of the electrocardiogram) prolonging compounds, QT shortening compounds, sodium channel blockers, calcium channel blockers, positive inotropes and chronotropes, and negative controls ( Supplementary Table 1 ).
QT Prolonging Compounds
There were 29 compounds included in the blinded test set which are known to prolong the QT interval in clinical and/or experimental settings (there were 24 unique compounds in the set with bepridil, BAY K 8644, JNJ-303, and terfenadine tested in duplicate or triplicate). The set of QT prolonging compounds elicit their effects through a variety of mechanisms including hERG block (eg. dofetilide), mixed channel effects (eg, ranolazine, bepridil, quinidine, terfenadine), or enhanced conductance of calcium (BAY K 8644) or sodium (veratridine) channels. Regardless of mechanism, exposure of the hiPS-CMs to the QT prolonging compounds resulted in a prolongation of the calcium transients (Figure 3 and Supplementary Figs. 2A and D) In this study all 24 QT prolonging compounds increased the duration of the calcium transient (Table 1) . Although not all compounds may be overtly arrhythmogenic, the increased duration of the calcium transient observed with these compounds correlates well with their observed experimental or clinical effects.
QT Shortening Compounds
There were 6 compounds in the blinded test set which are known to shorten the QT interval. Similar to the QT prolonging compounds, the QT shortening compounds act through a variety of mechanisms including activation of the K ATP channel (eg, pinacidil, nicorandil), activation of the hERG channel (eg, mallotoxin, NS1463) or through unspecified mechanisms (digoxin). With the exception of nicorandil (a weak opener of the K ATP channel), all shortened the calcium transient duration as expected (Table 2 and Figure 4 ; Supplementary Figs. 2E and F). Additionally, NS1643 was found to increase the beat rate at the 10 lM test concentration.
Sodium Channel Blocking Compounds
Sodium channel blocking compounds are divided into 3 classes (class 1A, 1B, and 1C) (Vaughan Williams, 1984) based on their binding kinetics with the sodium channel. However, their overall effects on AP duration and refractory period are complex due to varying abilities to block peak and late sodium currents as well as other channels, particularly hERG (eg, terfenadine; Lu et al., 2012) . In this study, 8 sodium channel blockers representing a wide range of activities were included in the test set (Table 3 ). There were 2 class 1A compounds in this test set, quinidine and procainamide. Both compounds are known to prolong the AP and as would be expected, both compounds caused a significant prolongation of the calcium transient. There were 3 class 1B compounds that displayed mixed effects on the calcium transients. Primidone had no significant effect on the calcium transient. Mexilitene caused a slight increase in both the rise time and the duration of the calcium transient at 10 mM and blocked the spontaneous beating activity of the cells at 100 mM. Phenytoin caused a dose-dependent reduction in the calcium transient duration. There were also 3 class 1C compounds tested. Flecainide caused a significant increase in the transient duration up to 1 lM and stopped all beating activity at the 10 lM test concentration. Propoxyphene caused a decrease in the transient duration at 10 lM and stopped all beating activity at the 100 lM test concentrations. Terfenadine, a potent sodium channel blocker, as well as a hERG blocker (Lu and Wang, 1999; Lu et al., 2012) , was included in the blinded test set 3 times to assess repeatability of the assay. In 1 of the 3 replicates a prolongation of the transient was observed at 1 mM. The dose response curves for the second and third repeats of terfenadine did not demonstrate a prolongation of the transient. However, the dose-response curves for the second and third tests did not include the 1 mM test concentration, only 0.5 mM. In all 3 tests of terfenadine the cells stopped beating at the 10 lM test concentration.
Calcium Channel Blocking Compounds
In general calcium channel blocking compounds were expected to cause a reduction in both the transient duration and the peak height. Table 4 reports the results of 4 calcium channel blockers (verapamil tested in duplicate). In each case the duration and height of the calcium transient was reduced (Figure 5 and Supplementary Figs. 2G and H) . Interestingly, an increase in the beat rate was observed for all compounds at the higher test concentrations. The reasons why calcium antagonists increased beat rate are unknown, although it has been a consistent finding in hiPS-CMs across a number of different assay systems (Braam et al., 2010; Guo et al., 2011) .
Positive Inotropic/Chronotropic Compounds
As expected, the sympathomimetics isoprenaline and phenylephrine, and the cAMP enhancer forskolin, increased beating rate, markedly in the case of the beta receptor agonist isoprenaline ( Figure 6 and Table 5 ). Serotonin, which has many cardiac effects, and the autacoid histamine also increased the beating rate.
Miscellaneous Effects and Negative Controls
There were a collection of compounds that were included in the test set which were either negative control compounds or compounds with miscellaneous mechanisms of action (Table 6 ). The test set included 3 negative control compounds: aspirin, cetirizine, and glucose. Only glucose showed an effect with a small non dose-dependent increase in transient duration (CTD75 10%-12% higher than control) evident across the entire dose range.
Many of the remaining compounds did not elicit an effect in this model system due to a number of reasons, including time of exposure and their mechanisms of action requiring other components of the heart which may or may not be represented in this in vitro system. Arsenic trioxide, which is known to inhibit hERG trafficking with long-term exposure was included in the test set. However, since the protocol used for this study only examined the effects of acute compound exposure, arsenic trioxide had no effect in this study, as would have been expected from its longer-term effects on hERG trafficking (Ficker et al., 2004) . Carbachol, atropine and tertiapin, compounds with both positive and negative chronotropic effects through complex mechanisms of action had no effect on the calcium transient kinetics or beat rate in this assay in this assay. The lack of effects of atropine and tertiapin were not unexpected as these compounds, at least in part, increase sino-atrial node firing and cardiac beat rate through vagal nerve inhibition, which is not recapitulated in this in vitro model (Kitamura et al., 2000; Yamada, 2002) . Carbachol elicits a negative chronotropic effect through activation of the K ACh channel in nodal, atrial and Purkinje cells (Yamada, 2002) . Here, carbachol caused an increase in the variability of the beating rate but a significant reduction in the beat rate was not observed. The final compounds in the set included propranolol, which had no effect at lower concentrations but caused a prolongation of the transient at 10 lM. This effect at higher concentrations may be due to hERG blockade or to membrane stabilizing effects. Two experimental drugs, the I KUR (rapid outward K þ current) blocker DPO-1 and the gap junction blocker carbenoxolone, caused a slight reduction of the transient duration.
DISCUSSION
The only existing requirement for in vitro cardiovascular safety testing of new compounds before first-in-human (FiH) exposure is the "ICH S7B" hERG test, which is not adequate to detect the proarrhythmic potential of drugs (Lu et al., 2008) , and most groups involved in drug discovery adopt more wide-ranging testing before FiH trials (Bowes et al., 2012) . Compound-induced alterations in the AP that lead to arrhythmia can be caused by either direct agonist or antagonist effects on the ion channels which contribute the generation of the AP, or through other signaling cascades which regulate the activity or expression levels of these channels. The currently available high throughput assays used in early drug de-risking focus on single ion FIG . 6. A and B , The sympathomimetic, isoprenaline, caused a dose dependent increase in the beat rate which was accompanied by a shortening of the transient duration and an increase in the peak height. C and D, Similarly, the adenylyl cyclase agonist, forskolin, caused an increase in beat rate accompanied by a decrease in transient duration and an increase in peak height. Bar graphs show mean and standard deviation. channels and/or utilize models that do not reproduce the complexity of cardiac physiology. However, stem cell technology can now provide a renewable and scalable source of human cardiomyocytes that can recreate many of the features of cardiac physiology and be used at a much earlier de-risking phase. These models allow for the development of high throughput, integrated assays that can query a wide range of potential cardiac effects and/or arrhythmogenic mechanisms due to compound exposure in the context of a functional human cardiomyocyte (Blazeski et al., 2012a,b; Dick et al., 2010) . Compound-induced alterations in the frequency, shape, or duration of the APs, due to effects on cardiac ion channels or cardiac signaling pathways, are reflected in changes to the shape and duration of the resulting calcium transient (Cerignoli et al., 2012; Qian and Guo, 2010) . Therefore, calcium transients can be used, as a surrogate method, to detect compound effects that may lead to arrhythmia through a variety of mechanisms. Additionally, using calcium transient analysis as an endpoint also allows for the detection of compounds that may have effects on calcium handling. To take advantage of these stem cell-derived cardiomyocyte models we utilized the KIC, which provides for high throughput, automated cell-by-cell analysis of intracellular calcium transients (Cerignoli et al., 2012) . This study reports the findings of a complete, blinded characterization of 53 unique compounds with many different mechanisms of action. Many are standard drugs with potentially adverse cardiac effects, others are reference compounds known to be cardioactive, and several inactive compounds were included (all in random order). For understanding the reproducibility of the screen, several of the compounds were tested in duplicate or even in triplicate.
Behavior of the Cells and General Assay Observations
The cell line used proved easy to handle, and showed very consistent calcium transient kinetics and beating rates for all 30 plates of cells used in this study. The repeatability of the measurements across all 30 plates demonstrates the robustness and reliability of the assay and provides confidence in deploying this assay for the frontline de-risking of compound series. However, we did note that the baseline spontaneous beating rate of the cardiomyocytes used in this study was very low. Here the measured baseline beating rate was around 15 beats per minute. This is at the low end of the spontaneous beating rates measured using the same cell line in other systems, where beat rates between 15 and 60 beats per minute have been reported Lee et al., 2012; Ma et al., 2011; Sirenko et al. 2013) . In previous experiments using KIC, we typically observed a beat rate of between 20 and 25 beats per minute. All cells used in this study were from the same lot which may suggest that the slower beat rate observed here might be due to lot-to-lot differences in the manufacturing of the cells. As a result of the slower beating rate there may be an increase in the sensitivity of the assay to hERG blockers, which are well known to display reverse rate-dependence (Sharma et al., 1999) . Conversely, the ability of the test to evaluate the effects of sodium channel blockers, which display marked positive rate dependence, may have been reduced.
This study was carried out using a period of spontaneous beating for each well, followed by a short period of electrical stimulation, at 45 beats/min. Because it is well known that the QT interval in vivo is influenced by the beating frequency, this seemed a useful strategy to avoid the complication of examining compound effects across wells with different beating frequencies. However, the well-to-well and plate-to-plate differences in beating frequency were relatively small and in general the results for spontaneous and for electrically stimulated conditions were found to be similar ( Supplementary Table  2 ). Therefore, the results from the analysis of the spontaneous beating activity were presented here. The results of the electrically stimulated effects suggest that future studies and routine use of this assay can consider analysis of spontaneously beating cells as an effective method for front line screening studies.
To investigate possible drug effects on the shape and duration of the calcium transient, a range of parameters are calculated from the data, as described in detail in the first part of the study (Cerignoli et al., 2012) . However, examination of the results suggested that most drug effects could be recognized using a subset of the measurements that focus on transient duration (ie, FWHM and CTD75) and beat rate. This approach is particularly useful for rapid assessment on compound effects across compounds series. Decision-making and prioritization of compounds is simplified when only 1 or 2 measurements need to be considered. While not necessary for identifying compound effects as a front-line screen, the complete set of measurements does allow for detailed analysis of calcium transient kinetics to be carried out and may be useful for follow on examinations of compound effects such as mechanistic and structure activity relationship studies.
Effects of the Compounds on Calcium Transient Kinetics
To test whether a single assay could be used to examine the full spectrum of effects that a compound may have on cardiac excitability a set of test compounds covering a number of different possible mechanisms were investigated. The test set included compounds that are known to prolong the QT interval, compounds which shorten the QT interval, compounds with positive inotropic and chronotropic effects, and compounds that block sodium and calcium channels.
Within the set of compounds that are known to increase the QT interval there was a range of mechanisms represented. This included a series of drugs that primarily prolong the QT interval through hERG channel block such as dofetilide, sotalol, and E4031. In this assay, exposure to these compounds caused significant prolongation of the calcium transient as expected. However, one of the shortfalls of the ICH SH7B guidelines for hERG testing is that there are other mechanisms that can cause prolongation of the QT interval independent of hERG channel block and QT prolongation per se is not the only or major factor leading to proarrhythmia. Several of these other mechanisms were represented within this set of test compounds. Veratridine, for example, causes a persistent opening of the sodium channel, leading to a prolongation of the AP. In this study, veratridine caused a significant prolongation of the calcium transient at 1 mM, which is consistent with previous studies examining AP prolongation in guinea-pig papillary muscle preparations and isolated perfused rabbit hearts (Honerjä ger and Reiter, 1975; Milberg et al., 2005) . Ivabradine blocks the I f (hyperpolarization activated pacemaker current) current and has been shown to prolong cardiac repolarization in both human and dog (Koncz et al., 2011) . In cardiac preparations from both these model systems a small increase in AP duration was noted at 1 lM, with more pronounced effects occurring at 10 mM. The results observed in the present assay mirror these findings, with a slight effect noted at 1 lM and a significant prolongation of the calcium transient was observed at the 10 lM test concentration of ivabradine. The I TO blocker 4-aminopyridine (4-AP) has been shown to cause a prolongation of the AP in a number of studies including those utilizing both human embryonic stem cell derived cardiomyocytes as well as human ventricular heart slices (Camelliti et al., 2011; Reppel et al., 2007) . Consistent with these previous results we found that 4-AP caused a prolongation of the calcium transient at the 100 lM test concentration (a concentration that prolonged human [but not canine] slice field potential duration [Camelliti et al., 2011] ).
Although the association of delayed cardiac repolarization and the precipitation of life-threatening arrhythmias is well recognized, the effects of QT shortening and the risk of developing ventricular tachycardia and/or ventricular fibrillation is less appreciated (Lu et al., 2008) . In addition to the QT prolonging compounds, this test set also included 6 test compounds known to shorten the QT interval through several different mechanisms. Compounds that fall into this category included the hERG channel activators NS1643 and mallotoxin, both of which caused a significant reduction in calcium transient duration. NS1643 demonstrated a significant shortening effect at 10 lM which is consistent with previous studies using isolated perfused rabbit heart models, which showed a reduction in APD 90 at 3 lM (Lu et al., 2008) . Mallotoxin demonstrated a reduction in the calcium transient duration with shortening beginning at 100 nM and reaching maximum effect at 1 lM, which is consistent with the reported EC 50 for increased K þ conductance through hERG channels of 320-520 nM for mallotoxin (Zeng et al., 2006) . Agonists of the K þ ATP channel are well known to decrease AP duration in a number of preclinical models (Lu et al., 2008) . In this study, the K þ ATP channel openers levcromakalim and pinacidil caused a significant shortening of the calcium transient duration at 1 lM and 100 nM, respectively. Nicorandil, on the other hand, had no effect in this assay. However, Nicorandil is considered only a weak activator of the K þ ATP channel (Shindo et al., 1998 ) whose primary effect is found on vasculature. Digoxin is also known to shorten AP duration, although the exact mechanism is not well understood. In this study, digoxin shortened the calcium transient duration at the 5 lM test concentration which is consistent with effects observed in guinea-pig hearts and rabbit ventricular wedge preparations at equivalent concentrations (Kocic and Korolkiewicz, 1998; Lu et al., 2013) .
Sodium channel blockers represent a complex collection of compounds that have varying abilities to block both the peak and late sodium current, as well some other ion channel currents, particularly hERG. These characteristics lead to sodium channel blockers having varied effects on the excitability of the cardiomyocyte. In electrophysiological studies the rate of rise of the cardiac AP ("phase 0") is a sensitive measure of the activity of the sodium channel, and is a useful indicator of sodium channel blockade. Although some of the sodium channel blockers tested did somewhat reduce the rate of rise of the calcium transient (ie, the "rise time" was increased), the parameter was not particularly sensitive. This may be directly related to the use of calcium transients as a surrogate for the integrated electrophysiological readout. The sodium current is very rapid (<5 ms) and the resultant membrane depolarization leads to the opening of the L-type channel, which triggers the intracellular calcium transient. Since the calcium transient is not initiated until after depolarization of the membrane reaches the threshold level for opening of the L-type calcium channel, at which point the sodium current is nearly complete, this approach may not be well suited to picking up subtle changes in sodium channel conductance. Additionally, one of the primary concerns with hIPS-CM models is the low level of sodium channel expression and additionally the low basal heart rates, given that Na þ blockade effects are rate dependent and easier found at higher frequencies of beating. With the caveats that fast sodium current measurement is technically challenging, and that ionic current data in human myocytes is sparse and often in diseased cells, the gating and density of this current along with the other primary determinants of the AP in this cell line have been shown to be similar to human cardiac myocytes (Ma et al., 2011) . Studies in other stem cell-derived cardiomyocyte models have suggested that even when sodium current does not reach the level of mature cardiomyocytes of a similar genetic background, these models can be useful in the assay of both gain-and lossof-function sodium channel effects (Davis et al., 2012) . Taken together the timing of the calcium transient relative to the AP "phase 0," and any relative differences in expression of sodium channels might explain the varied effects observed with the compounds with a more "pure" sodium channel blocking effect such as mexiletine, primidone, and phenytoin. For several of the sodium channel blockers the most reliable signal we observed was the cessation of beating at a threshold concentration (4/8 compounds), which would be consistent with a complete block of the sodium current.
When we consider the effects of individual compounds classed as sodium channel blockers, compounds which also block hERG and are known to prolong the QT interval such as the Class 1A compounds, quinidine and procainamide as well as the Class 1C compound flecainide were found to cause a significant prolongation of the calcium transient. In this study, propoxyphene caused a reduction in the calcium transient duration at 10 lM and the cells stopped beating at 100 lM. This result is consistent with findings in both isolated rabbit wedge model and isolated canine Purkinje fibers, which demonstrated a 13.8% reduction in APD 95 at 3 lM (Holland and Steinberg, 1979) . Terfenadine, an anti-histamine drug with Class 1C characteristics, is a complex drug that blocks Na þ , hERG, and Ca 2þ channels (Lu et al., 2012) . In the rabbit ventricular wedge model, terfenadine caused a slight prolongation of the QT interval at 1 mM and elicited ventricular tachycardia/ fibrillation at 10 mM (Lu et al., 2012) . In this assay we only tested the 1 mM concentration in 1 of the 3 terfenadine dose response curves and we did find a mild prolongation of the calcium transient. However, we also found that terfenadine consistently caused a cessation of the spontaneous beating activity at 10 lM.
Compared to the relative complexity of the sodium channel blockers, the results of the calcium channel blockers were straightforward. In all cases the calcium channel blockers caused a reduction in both the peak height and the transient duration as would be expected. Similarly, we found that all of the positive inotropic/chronotropic compounds caused a decrease in the Ca 2þ transient duration and an increase in the beat rate.
Finally, there were a number of compounds with miscellaneous mechanisms that were included in the test set which do not fall into the other categories. Some of these were "negative controls," such as aspirin, glucose, or cetirizine. Aspirin and cetirizine had no effect on the calcium transient duration. Glucose did cause a change in the transient duration at the highest concentrations (0.5 mM) but these effects were relatively small.
Several of these compounds act through complex signaling pathways or their effects are specific to certain cell types within the heart. The QT-prolonging compound arsenic trioxide had no effect, but this compound is known to be an inhibitor of hERG trafficking (Wible et al., 2005) , and its effects are not observed acutely, therefore this is an expected result. The cholinergic LU ET AL. | 513 agonist carbachol is a parasympathominetic that stimulates both muscarinic and nicotinic receptors, and elicits a negative chronotropic effect through activation of the K Ach channel in nodal, atrial and Purkinje cells. However, in this study carbachol had no effect on the beat rate. Although the model system includes a pan-cardiac mix of cardiomyocytes, these cultures do not contain any neural network cells, and therefore we would not expect that carbachol have a strong beat rate effect. The I KUR blocker DPO-1 is expected to prolong AP duration in atrial cells but not in ventricular cells (Lagrutta et al., 2006; Tinker and Harmer, 2010) . Here, we found a small but significant dose-dependent reduction in the calcium transient duration with exposure to DPO-1. Similarly, the gap junction blocker carbenoxolone caused a small but significant dose-dependent reduction in the transient duration. It should be noted that little is known about the effect of these compounds on calcium transients in other cardiomyocyte model systems. Propranolol had no effect at lower concentrations, however at 10 lM there was a prolongation of the transient observed. This result may be expected as beta blockers have minimal effect on resting subjects and the cells were already demonstrating a slow beat rate. The prolongation of the calcium transient that was observed at the higher concentration could be due to blockade of the hERG channel which occurs within this concentration range (Polak et al., 2009) , through membrane stabilizing effects (Godin et al., 1976) , or a combination of these 2 effects. Neither atropine nor teriapin caused an increase in beat rate which may be expected as both compounds primarily act through vagal nerve inhibition to increase beating rate.
Reproducibility of Repeated Compounds
Several of the compounds in the blinded test set were included in duplicates or even triplicate to test the reproducibility of the assay. In general, the results from the 6 blinded compounds which were tested in duplicate (bepridil, Table 2 ; Bay K 8644, Table 2 ; verapamil, Table 4 ; forskolin, Table 6 ; JNJ 303, Table 1) or triplicate (terfenadine, Tables 1 and 3) were consistent. The exception was compound JNJ 303, which only demonstrated a small and non-dose-dependent increase in the transient duration in one of the replicate tests. This marginal response for JNJ 303 is consistent with other studies which have shown that stem cell-derived cardiomyocytes have a weak response to I Ks blockers (eg, Braam et al., 2013) .
Advantages and Limitations of the Assay
Overall this study demonstrated the utility of both the stem cell-derived cardiomyocyte model and the use of high throughput calcium transient analysis as a method for de-risking compound series. This approach was able to detect a range of compounds with potentially harmful effects such as QT prolonging compounds, QT shortening compounds, compounds with effects on beat rate and compounds which block sodium and calcium channels using a single assay. Many of these effects would be difficult to detect using traditional front line screens that look at compound effects on a single ion channel, typically hERG, and would require the data from multiple assays to be assembled for each compound in order to recognize these effects. Additionally, since this is a high throughput approach thousands of compounds per year can be analyzed, which would allow this assay to be utilized very early in the discovery process.
The hSC-derived cardiomyocyte models have been demonstrated by ourselves and others as potentially being a very useful model system for making predictions about compound effects in vivo (Cerignoli et al., 2012; Guo et al., 2011) . However, with all experimental methods it is important to recognize not only the capabilities of an assay system but also the limitations. This is crucial when considering in vitro methods which will be used to make predictions about expected clinical compound effects. The predominant criticism of any of the hSC-derived cardiomyocytes models is that they possess an immature phenotype. The current hSC cardiomyocyte models do not demonstrate the rod-shaped morphology of adult cardiomyocytes, do not possess a T-tubule system, express many of the cardiac ion channels at lower levels than in adult cells, and demonstrate spontaneous beating (Blazeski et al., 2012a; Dick et al., 2010) . Many of these morphology and maturity issues are likely due to the 2-dimensional culture system. In fact, it should be recognized that even primary adult cardiomyocytes will lose their rod-shaped morphology and take on the spread morphology exhibited by the hSC-derived cardiomyocyte models when they are maintained long term in a 2-dimensional culture system (Qian and Guo, 2010) . However, in this study and in other studies using the same cell model, the cells, regardless of their relative immaturity, have proven to be sensitive to most of the compounds tested, which suggests that they are fit for the purpose of phenotypic compound screening, and further work to improve the maturity of the cells should only enhance their current utility. We expect that future improvements in differentiation and culture protocols that result in a more mature phenotype will only increase the utility of the model.
In this study, one of the primary concerns was the low beat rate that was observed. This may have contributed to the mixed responses to Na þ channel blocking agents (which are more effective at higher beating frequencies), but may increase the sensitivity to hERG blockers, which show reverse use dependency (eg, Sharma et al., 1999) . Second, the slow beating rate, while potentially increasing the sensitivity to positive chronotropic agents such as isoprenaline, possibly makes the cells less sensitive to agents which could slow the heart rate, which may explain the lack of effect observed with carbachol.
Although most of the negative controls did not have effects, we did see a small but significant increase in the transient duration with glucose. This effect could be linked to a metabolic effect but it is unclear whether this would be expected as the modified Tyrode's solution used in this assay contains 10 mM glucose. This study was designed to focus on positive compounds with a range of mechanisms of action important in cardiac electrophysiology. Future studies using this platform should include a larger number of negative compounds in order to assess specificity and accuracy of the assay.
Of course the cells suffer from similar problems encountered with other in vitro systems in that they do not model the interaction of one organ system with another. For example, because the cells are not innervated, compounds that elicit cardiac effects by acting on the nervous system may not be picked up. In the compound set used in the current study this was seen with atropine and tertiapin, neither of which had an effect on the cells. Both of these compounds elicit their cardiac effects, at least in part, through vagal nerve inhibition, leading to an increase in the firing rate of the sinoatrial node.
To visualize the calcium transients this method utilizes a calcium sensitive fluorescent dye that has the disadvantage of being bleached by the excitation light, so the exposure of individual wells to the exciting light should be limited. In this study, 10 s recordings of transient activity were made from each well and we have previously recorded up to 20 s without significant bleaching of the dye. However, recording calcium transient activity for several minutes would likely result in significant loss of signal due to bleaching. Calcium indicators such as Fluo-4 are, by definition, "calcium buffers" which can affect physiological signaling (Paredes et al., 2008) , and in addition, Fluo-4 has been reported to reduce the beating rate of isolated rabbit sino-atrial cells (Monfredi et al., 2013) . However, Fluo-4 is relatively free of buffering effects compared with higher affinity indicators and less prone to intracellular compartmentalization than lower affinity indicators (Paredes et al., 2008) , and as such is used routinely for calcium imaging in many different assay systems. In this assay we have the advantage of being able to significantly reduce the amount of Fluo-4 used to one-quarter the standard amount, due to the extremely high sensitivity of the KIC system.
There are many other technologies including multielectrode array, voltage AP and calcium transient assay using various fluorescent reporters, impedance-based assays, image-based assay, being applied in the cardiac safety tests Harris et al., 2013) . Future studies are wanted to compare the different technologies using hiPS-CMs for cardiac toxicity screen.
In summary, this study has shown that the KIC technology gives consistent and reproducible screening results in a HTS mode. In order to test feasibility of deploying this high content assay early in the drug discovery process in order to identify compounds with a cardiac safety liability and help prioritize compound series we ran a series of 60 blinded compounds (53, some duplicated) through the assay. The results demonstrate that the assay was able to identify most compounds linked to adverse cardiac effects within the expected concentration ranges. It is evident from the results that this screening model is sensitive to compounds which either prolong or shorten the QT interval, compounds which increase the beat rate and compounds which block the calcium channel and to a certain extent compounds that block the sodium channel. As all of these outcomes can be elucidated using a single assay, this novel technology may be an early discovery replacement for hERG screening, because even with the above limitations it gives good phenotypic readouts, allowing better decisions based on integrated responses from a functional, human, cell model.
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